Home

Fairmount Funds Management LLC

CIK 1802528 · last filed 2026-06-23

Fairmount Funds Management LLC is a corporate insider who has filed 28 SEC Form 4 insider transactions across 8 companies since 2020. The most recent filing, for ORKA, was dated Jul 1, 2026. Across all open-market trades the lifetime net is −$1.33B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $329.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$329.46M

Companies

8

Total Filings

28

Lifetime Open-Market Net

-$1.33B

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SYRE Director 0 $99.96 $0 -$1.60B 3 2026-06-23
JBIO Director — $19.70 — $0 1 2026-06-11
VRDN Director 5,090,928 $19.51 $99.32M $279.99M 6 2026-05-13
COGT Director 5,503,418 $40.67 $223.82M -$82.90M 7 2026-01-22
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Director 2,747,866 $15.70 $43.14M $72.95M 1 2025-12-08
APGE Director — $134.17 — $0 1 2025-06-20
DNTH Director 62,146 $101.61 $6.31M $0 2 2024-04-01
Cogent Biosciences, Inc. (UMRX) Delisted 10%+ Owner 1,147,406 — — $0 2 2020-07-13

Recent Filings

28 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-01 ORKA Notice (144) −3,553,410 -$300.01M EDGAR
2026-06-23 SYRE Notice (144) −4,684,781 -$399.66M EDGAR
2026-06-23 SYRE Mixed −16,072,404 -$1.60B EDGAR
2026-06-11 JBIO Grant (A) — $0 EDGAR
2026-05-13 VRDN Buy (P) +3,529,410 $60.00M EDGAR
2026-03-31 COGT Notice (144) −7,000,000 -$242.62M EDGAR
2026-01-22 COGT Sell (S) −3,500,000 -$127.40M EDGAR
2026-01-22 COGT Notice (144) −3,500,000 -$127.40M EDGAR
2026-01-22 APGE Notice (144) −1,750,000 -$133.53M EDGAR
2025-12-08 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Buy (P) +5,440,000 $72.95M EDGAR
Showing 1–10 of 28
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.